

DAFTAR PUSTAKA

1. Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile idiopathic arthritis. *Balkan Med J.* 2017;34(2):90–101.
2. Lovell DJ. Juvenile Idiopathic Arthritis. In: Klippel, J.H., Stone, J.H., Crofford, L.e.J., White PH, editor. *Primer on the Rheumatic Disease*. 13th editi. Boston: Springer; 2008. p. 142–8.
3. Goldmuntz, EA, White P. Juvenile idiopathic arthritis: A review for the pediatrician. *Pediatr Rev.* 2006;27(4):e24–32.
4. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. *Lancet.* 2011;377(9783):2138–49.
5. Cummins C, Connock M. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept HTA Health Technology Assessment NHS R&D HTA Programme. *Health Technol Assess (Rockv).* 2002;6(17).
6. Ghrahani R, Setiabudiawan B, Sapartini G, Puspasari H. Distribusi Subtipe Juvenile Idiopathic Arthritis di Bandung Distribution of Juvenile Idiopathic Arthritis Subtypes in Bandung. *Maj Kedokt Bandung.* 2012;44(2):101–5.
7. Pribadi A, Tambunan T. Profil Kasus Artritis Idiopatik Juvenil (AIJ) Berdasarkan Klasifikasi International League Against Rheumatism (ILAR). *Sari Pediatr.* 2008;9(6):370–4.
8. Miller ML CJ. Juvenile rheumatoid arthritis. In: Behrman RE, Kliegman RM JH, editor. *Nelson’s textbook of pediatrics*. 17th editi. Philadelphia: W.B. Saunders; 2004. p. 799–805.
9. Article S. Report of the American College of Rheumatology Pain Management Task Force. *Arthritis Care Res (Hoboken).* 2010;62(5):590–9.
10. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res (Hoboken).* 2011;63(4):465–82.
11. Jane Munro et al. Clinical guideline for the diagnosis and management of juvenile



- idiopathic arthritis. The National Health and Medical Research Council of Australian Government. 2009. 1-43 p.
12. Shyen S, Amine B, Rostom S, EL Badri D, Ezzahri M, Mawani N, et al. Sleep and its relationship to pain, dysfunction, and disease activity in juvenile idiopathic arthritis. *Clin Rheumatol*. 2013;33(10):1425–31.
 13. Stinson JN, Hayden JA, Ahola Kohut S, Soobiah C, Cartwright J, Weiss SK, et al. Sleep problems and associated factors in children with juvenile idiopathic arthritis: a systematic review. *Pediatr Rheumatol Online J*. 2014;12:19.
 14. Tejada P, Enríquez E, María Rodríguez del Valle J, Barceló A, Gutiérrez E, De Inocencio J. Juvenile idiopathic arthritis-associated uveitis complicated by glaucoma and Brown's syndrome. *Rheumatol (United Kingdom)*. 2012;51(9):1729–30.
 15. Sijssens KM, Rothova A, Berendschot TTJM, de Boer JH. Ocular Hypertension and Secondary Glaucoma in Children with Uveitis. *Ophthalmology*. 2006;113(5).
 16. Petty RE, Southwood TR, Manners P, Baum J GD, Goldenberg J et al. International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis : Second Revision , Edmonton , 2001. *J Rheumatol*. 2001;31: 390–2.
 17. Akib AA. Artritis Idiopatik Juvenil Kesepakatan B aru Klasifikasi dan Kriteria Diagnosis Penyakit Artritis pada Anak. *Sari Pediatr*. 2003;5(2):40–8.
 18. Hahn Y-S, Kim J-G. Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis. *Korean J Pediatr*. 2010;53(11):921.
 19. Petty R, Laxer R, Lindsley C WL. Juvenile Idiopathic Arthritis. In: Petty R, Laxer R, Lindsley C et al (Eds), editor. *Textbook of Pediatric Rheumatology*. 7th editio. Saunders; 2015. p. 188–204.
 20. Hospach T, Maier J, Müller-Abt P, Patel A, Horneff G, von Kalle T. Cervical spine involvement in patients with juvenile idiopathic arthritis - MRI follow-up study. *Pediatr Rheumatol*. 2014;12(1):1–7.
 21. Lambot K, De Somer L, Breton S, Wouters C, Bader-Meunier B, Brunelle F. Juvenile idiopathic arthritis with dry synovitis: Clinical and imaging aspects in a cohort of 6 patients. *Pediatr Radiol*. 2012;42(Suppl 1):S491.
 22. Zeng P, Li F, Zeng H. Occult macrophage activation syndrome in systemic-onset juvenile idiopathic arthritic syndrome--a case report. *Acta Reum Port*. 2013;38(3):196–200.



23. Sawhney S. The macrophage activation syndrome: a new entity, a potentially fatal complication of rheumatic disorders. *Arch Dis Child*. 2001;85:421–6.
24. Saboo US, Metzinger JL, Radwan A, Arcinue C, Parikh R, Mohamed A, et al. Risk factors associated with the relapse of uveitis in patients with juvenile idiopathic arthritis: A preliminary report. *J AAPOS*. 2013;17(5):460–4.
25. Wallace CA. Current management of juvenile idiopathic arthritis. *Best Pract Res Clin Rheumatol*. 2006;20(2):279–300.
26. Giancane G, Consolaro A, Lanni S, Davì S, Schiappapietra B, Ravelli A. Juvenile Idiopathic Arthritis: Diagnosis and Treatment. *Rheumatol Ther*. 2016;3(2):187–207.
27. Maldyk P, Rutkwoska L, Lisowska B. Knee synovectomy in children with juvenile idiopathic arthritis. *J Pediatr Orthop Part B*. 2008;17(3):128–30.
28. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. *Arthritis Care Res (Hoboken)*. 2011;63(4):465–82.
29. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: A revolution in care. *Pediatr Rheumatol*. 2014;12(1):1–10.
30. Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: Short- and long-term efficacy and safety results. *Arthritis Rheum*. 2005;52(2):563–72.
31. Huang J-L. New advances in juvenile idiopathic arthritis. *Chang Gung Med J*. 2011;35:1–14.
32. Espinosa M, Gottlieb BS. Juvenile Idiopathic Arthritis. *Pediatr Rev*. 2012;33(7):303–13.
33. Cunha ALG, Miotto e Silva VB, Osaku FM, Niemxeski LB, Furtado RNV, Natour J. Intra-articular injection in patients with juvenile idiopathic arthritis: factors associated with a good response. *Rev Bras Reumatol (English Ed)*. 2016;56(6):490–6.
34. Unsal E, Makay B. Intraarticular triamcinolone in juvenile idiopathic arthritis. *Indian Pediatr*. 2008;45(12):995–7.
35. Beresford MW, Baildam EM. New advances in the management of juvenile idiopathic



- arthritis - 1: Non-biological therapy. Arch Dis Child Educ Pract Ed. 2009;94(5):144–50.
36. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate in rheumatoid arthritis: Optimizing therapy among different formulations. Current and emerging paradigms. Clin Ther. 2014;36(3):427–35.
 37. Visser K, Van Der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: A systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094–9.
 38. Ramanan A V., Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child. 2003;88(3):197–200.
 39. Funk RS, Becker ML. Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: striving for individualized therapy Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: striving for individualized therapy. Expert Rev Precis Med Drug Dev. 2016;1(1):53–68.
 40. Salgado E, Maneiro JR. [New therapies for rheumatoid arthritis.]. Med Clin (Barc). 2014;90–2.
 41. Wood AJJ, Olsen NJ, Stein CM. New Drugs for Rheumatoid Arthritis. N Engl J Med. 2004;350(21):2167–79.
 42. Oen K, Duffy CM, Tse SML, Ramsey S, Ellsworth J, Chédeville G, et al. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res (Hoboken). 2010;62(4):527–36.
 43. Edelsten C, Lee V, Bentley CR, Kanski JJ, Graham EM. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol. 2002;86:5156.
 44. Guillaume S, Prieur A; Coste J, Deslandre C. Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis oligoarticular-onset Juvenile Idiopathic Arthritis. 2015;131(August 2000):1858–65.
 45. Guzman J, Oen K, Huber AM, Duffy KW, Boire G, Shiff N, et al. The risk and nature of flares in juvenile idiopathic arthritis: Results from the ReACCh-Out cohort. Ann Rheum Dis. 2016;75(6):1092–8.



46. Shoop-Worrall SJW, Kearsley-Fleet L, Thomson W, Verstappen SMM, Hyrich KL. How common is remission in juvenile idiopathic arthritis: A systematic review. *Semin Arthritis Rheum.* 2017;47(3):331–7.
47. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. *Arthritis Care Res.* 2011;63(7):929–36.
48. Felson D. Defining remission in rheumatoid arthritis. *Ann Rheum Dis.* 2012;71.
49. Ece A, Şen V, Yel S, Güneş A, Uluca Ü, Tan İ, et al. Clinical and Laboratory Characteristics and Follow Up Results of 121 Children with Juvenile Idiopathic Arthritis. *Eur J Gen Med.* 2015;10(3):136–41.
50. Fernandes T a. P, Corrente JE, Magalhães CS. Remission status follow-up in children with juvenile idiopathic arthritis. *J Pediatr (Rio J).* 2007;83(2):141–8.
51. Edalat F. Defining remission in rheumatoid arthritis. NIH Public Access. 2012;40(6):1301–15.
52. Stinson JN, Luca NJC, Jibb LA. Assessment and management of pain in juvenile idiopathic arthritis. *Pain Res Manag.* 2012;17(6):391–6.
53. Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): An alternative therapy for autoimmune inflammatory myopathy. *Rheumatology.* 2005;44(3):386–9.
54. World Health Organization. WHO Growth Reference 5-19 years [Internet]. 2007 [cited 2018 May 2016]. Available from: http://www.who.int/growthref/who2007_bmi_for_age/en/